Discover. Oncology最新文献_第10页

Construction and validation of a cell-in-cell related prognostic signature for hepatocellular carcinoma. 肝细胞癌细胞内相关预后标记的构建和验证。

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-12 DOI: 10.1007/s12672-025-03245-0

Hao Zhong, Dong Wang, Yisheng Chen, Danhong Zhan, Chenxi Wang, Rongqi Lin, Wen Li, Qiang Sun, Ruizhi Wang, Meifang He

{"title":"Construction and validation of a cell-in-cell related prognostic signature for hepatocellular carcinoma.","authors":"Hao Zhong, Dong Wang, Yisheng Chen, Danhong Zhan, Chenxi Wang, Rongqi Lin, Wen Li, Qiang Sun, Ruizhi Wang, Meifang He","doi":"10.1007/s12672-025-03245-0","DOIUrl":"10.1007/s12672-025-03245-0","url":null,"abstract":"Cell-in-cell structures (CICs) and their biological roles contribute to disease development, particularly in cancer. However, the roles of CIC-associated genes (CICGs) in hepatocellular carcinoma (HCC) are largely unknown. This study sought to establish a a CICGs-linked HCC signature and assess its predictive significance. We acquired gene expression profiling data for tumor and normal tissues of HCC patients from The Cancer Genome Atlas (TCGA) for training and from the International Cancer Genome Consortium (ICGC) for validation. Consensus clustering was employed to delineate patient cohorts with varying prognoses, categorizing HCC patients into two distinct groups. A selection of fifty CICGs was compiled from the literature, revealing their association with CIC development through functional studies. Six predictive genes were ultimately identified through univariate Cox proportional hazards regression (Cox) and least absolute shrinkage and selection operator (LASSO) analyses. This prognostic signature, resulting from a multivariate Cox, subsequently segmented TCGA and ICGC cohort individuals into high- and low-risk categories. Our verification of the signature's precision involved survival analysis contrasts between those at high and low risk. Quantitative real-time PCR (qRT-PCR) analysis revealed markedly elevated expression levels of these six genes in HCC tumors compared to neighboring healthy tissue, underscoring their potential role in tumor development. This experimentally reinforces the accuracy of the genetic profile. We also examined variations in the composition of immune cells and immunological responses across high-risk and low-risk cohorts. This study established and verified prognostic variables connected to cell-in-cell (CIC), potentially improving personalized survival forecasts for patients with HCC.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1539"},"PeriodicalIF":2.9,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Independent effects of mental health disorders on breast cancer and their mediating factors: evidence from NHANES and two-step Mendelian randomization. 精神健康障碍对乳腺癌及其中介因素的独立影响：来自NHANES和两步孟德尔随机化的证据

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-12 DOI: 10.1007/s12672-025-03261-0

Kang Ma, Xueyan Mao, Hongkai Zhuang, Cheng Long, Bo Chen

{"title":"Independent effects of mental health disorders on breast cancer and their mediating factors: evidence from NHANES and two-step Mendelian randomization.","authors":"Kang Ma, Xueyan Mao, Hongkai Zhuang, Cheng Long, Bo Chen","doi":"10.1007/s12672-025-03261-0","DOIUrl":"10.1007/s12672-025-03261-0","url":null,"abstract":"Background: The epidemiological data regarding the correlation between mental disorders and breast cancer (BC) is still debatable. This study's objective is to clarify the connection between BC and mental disorders, such as depression, panic, and anxiety, in addition to examining the mediating role of risk factors associated with BC through genetic susceptibility.Methods: Cross-sectional data came from the National Health and Nutrition Examination Survey (NHANES) for the years 2015-2018, stratified by BC status. Summary statistics of genome-wide association studies (GWASs) of mostly European ancestry were used for Mendelian randomization (MR) analysis. The connections between depressive symptoms, anxious symptoms, and anxiety medication use and breast cancer were assessed using logistic regression models. The independent effects of depression, panic, and anxiety on BC were estimated through two-sample multivariable MR. Furthermore, 23 possible mediators of the connection were assessed and mediated proportions were computed using two-step MR.Results: Cross-sectional data revealed that participants taking medication for anxiety were at higher risk of BC (OR (95%CI): 2.18 (1.29-3.70), P < 0.01). Using multivariate MR to adjust for depression, anxiety, and panic, only anxiety was still strongly correlated with the occurrence of overall (βIVW (SE): 0.053 (0.016), P < 0.05) and ER- (βIVW (SE): 0.075 (0.025), P < 0.05) BC. After excluding 23 risk factors related to BC, no mediators were identified between anxiety and BC.Conclusion: Our findings suggests that anxiety susceptibility at the genetic level is a distinct risk factor for BC, with no mediators identified in this process.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1533"},"PeriodicalIF":2.9,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12343388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis. 低风险浸润性乳腺癌预先遗漏腋窝分期后选择性延迟前哨淋巴结活检的结果：回顾性假设模拟分析。

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-12 DOI: 10.1007/s12672-025-03344-y

Albin Bengtsson, Karolina Larsson, Kian Chin

{"title":"The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis.","authors":"Albin Bengtsson, Karolina Larsson, Kian Chin","doi":"10.1007/s12672-025-03344-y","DOIUrl":"10.1007/s12672-025-03344-y","url":null,"abstract":"Background: Sentinel lymph node biopsy (SLNB) is performed to guide recommendations on adjuvant treatments for invasive breast cancer. However, studies have shown oncological safety without SLNB in low-risk patients. We aimed to determine the clinical benefits of delaying SLNB (d-SLNB), if upfront axillary staging was omitted in patients with low-risk invasive breast cancers.Methods and materials: A retrospective hypothetical simulated analysis. Patients who had breast surgery and SLNB between 2019 and 2021 were included. Patients with low-risk invasive cancers were identified based on preoperative histopathology (≥ 65 years, Luminal A-like, T1, cN0, Grade 1-2). Outcome analyses were based on the Actual clinical management compared to two different hypothetical Scenarios: (A) upfront SLNB omission only, and (B) upfront SLNB omission with d-SLNB. Primary endpoints were proportion of patients suitable for SLNB omission, outcome of d-SLNB and changes in adjuvant treatments. Secondary endpoint was surgical costs.Result: Of 712 patients, 205 (30%) had low-risk invasive cancers and eligible for SLNB omission. In Scenario A, 25 (12%) patients with SLN metastases would have understaged. If Scenario B was applied, the false negative rate of axillary staging would reduce from 25 (12%) to 12 (6%) patients, p < 0.001. On average, adjuvant treatments were given to 73% (Actual clinical setting) vs. 27% (Scenario A) vs. 55% (Scenario B), p < 0.001. Based on 100 patients, d-SLNB was associated with an incremental cost of 55,000 EUR per 100 patients.Conclusion: Although upfront SLNB omission was associated with missed SLN metastases, majority of low-risk invasive cancers were SLN negative. Delayed-SLNB could provide additional useful information to guide adjuvant treatments.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1537"},"PeriodicalIF":2.9,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12343391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative systems biology and in-vitro analysis of cryptolepine's therapeutic role in breast cancer. 综合系统生物学和体外分析隐tolepine在乳腺癌中的治疗作用。

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-11 DOI: 10.1007/s12672-025-03158-y

Hina Qayoom, Pankaj Keshari, Manzoor A Mir

{"title":"Integrative systems biology and in-vitro analysis of cryptolepine's therapeutic role in breast cancer.","authors":"Hina Qayoom, Pankaj Keshari, Manzoor A Mir","doi":"10.1007/s12672-025-03158-y","DOIUrl":"10.1007/s12672-025-03158-y","url":null,"abstract":"Background: Breast cancer is the most diagnosed cancer in women and the second leading cause of cancer-related deaths worldwide. Chemotherapy faces challenges like drug resistance, side effects, and recurrence, underscoring the need for innovative therapies. This study explores cryptolepine, a natural compound, for its therapeutic potential against heterogeneous BC by targeting specific molecular mechanisms.Methods: we conducted an ADMET analysis to assess cryptolepine's pharmacokinetic properties and drug-likeness. Target prediction was performed using SWISS-TARGET-PREDICTION and Integrative Pharmacology for BC. Identified targets were cross-referenced with BC-related genes from Gene Atlas, TCGA, and OMIM. Protein-protein interactions were analyzed using STRING, and pathway enrichment was assessed using KEGG and ShinyGO. Molecular docking and dynamics simulations evaluated cryptolepine's binding efficacy while in-vitro assays, including proliferation studies and mRNA expression analysis, validated these findings.Results: Cryptolepine demonstrated favorable drug-likeness and multi-target activity, interacting with key cancer pathways such as p53, STAT3, and PI3K-Akt. Network pharmacology revealed its potential to reduce drug resistance. Cryptolepine regulated important genes (PTGS2, STAT3, CCND1) across critical pathways (cAMP, PI3K/AKT, P53, IL6/JAK2/STAT3). Molecular docking confirmed strong binding (ΔG - 8.2 kcal/mol), and in-vitro assays showed IC50 values of 4.6 μM for MDA-MB-231 and 3.1 μM for Mcf-7. mRNA expression analysis indicated increased cytochrome C and BAX, while pro-caspase levels decreased.Conclusion: Cryptolepine shows promise as a therapeutic candidate for BC. Future research should optimize its pharmacological profile for specificity and reduced toxicity.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1520"},"PeriodicalIF":2.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping the current research landscape of metformin in cancer based on bibliometric analysis. 基于文献计量学分析的二甲双胍在癌症中的研究现状。

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-11 DOI: 10.1007/s12672-025-03327-z

Yuan Wang, Sike He, Ziqi Li, Nan Jiang, Guangxi Sun

引用次数: 0

Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics. 使用新一代分析技术进行肿瘤个体化治疗的靶向药物监测。

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-11 DOI: 10.1007/s12672-025-03376-4

Wei Li, Chaoling Wen, Bin Ye, Pranjal Gujarathi, Meghraj Suryawanshi, Kuldeep Vinchurkar, Imtiyaz Bagban, Sudarshan Singh, Opeyemi Joshua Olatunji

{"title":"Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics.","authors":"Wei Li, Chaoling Wen, Bin Ye, Pranjal Gujarathi, Meghraj Suryawanshi, Kuldeep Vinchurkar, Imtiyaz Bagban, Sudarshan Singh, Opeyemi Joshua Olatunji","doi":"10.1007/s12672-025-03376-4","DOIUrl":"10.1007/s12672-025-03376-4","url":null,"abstract":"Therapeutic drug monitoring (TDM) is a clinical procedure aimed at maintaining plasma drug concentrations within a specific therapeutic range, thereby maximizing the safety and efficacy of pharmacological therapy. Conventional oncology strategies face challenges like non-specific toxicity, drug resistance, incomplete tumor eradication, high costs, and significant side effects that impact quality of life. Moreover, conventional therapy offers limited benefits in advanced stages, pose risks of secondary cancers and immune suppression, and lack personalization, highlighting the need for targeted, innovative approaches. In modern oncology, TDM has gained significant interest due to narrow therapeutic windows, significant inter-individual variability in pharmacokinetics, and the complexity of cancer pharmacotherapy. This study reviews the role of TDM in oncology with more emphasis on pharmacogenetic testing, immunoassays, and liquid-chromatography-mass spectroscopy (LC-MS/MS) techniques, highlighting its applications in optimizing the dose during immunotherapies, targeted therapies, and chemotherapeutics. Moreover, the review discusses the challenges and limitations associated with TDM in oncology, such as the requirement of robust clinical evidence, standardized practices, and integration with personalized medicine approaches. Emerging technologies, including AI and machine learning, are also considered for their potential to enhance TDM in oncology.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1523"},"PeriodicalIF":2.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent strategies in diagnosis, screening, prevention, and treatment of breast cancer in young women. 年轻女性乳腺癌的诊断、筛查、预防和治疗的最新策略。

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-11 DOI: 10.1007/s12672-025-03180-0

Dinesh Kumar Sharma, Rajeswari Saripilli

引用次数: 0

Clinacanthus nutans (Burm.f.) Lindau facilitates cuproptosis and ameliorates colon cancer progression by inhibiting PDE3B-mediated Apelin pathway. 胭脂虫（缅甸）Lindau通过抑制pde3b介导的Apelin通路促进铜质增生，改善结肠癌进展。

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-11 DOI: 10.1007/s12672-025-02037-w

Gaoyun Zhou, Xueying Lin, Zhiheng Lai, Dewen Su, Long Lin, Xuewu Chen

{"title":"Clinacanthus nutans (Burm.f.) Lindau facilitates cuproptosis and ameliorates colon cancer progression by inhibiting PDE3B-mediated Apelin pathway.","authors":"Gaoyun Zhou, Xueying Lin, Zhiheng Lai, Dewen Su, Long Lin, Xuewu Chen","doi":"10.1007/s12672-025-02037-w","DOIUrl":"10.1007/s12672-025-02037-w","url":null,"abstract":"Background: Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer.Methods: A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells.Results: CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway.Conclusion: Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1521"},"PeriodicalIF":2.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of advanced diagnostics on precision medicine in hemato oncology. 先进诊断学在血液肿瘤精准医学中的作用。

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-11 DOI: 10.1007/s12672-025-03169-9

Befikad Mandefro, Dereje Mengesha Berta, Amanuel Kelem, Bisrat Birke Teketelew, Abateneh Melkamu, Yalew Much, Zewdu Mulatie, Tiruneh Adane

{"title":"The role of advanced diagnostics on precision medicine in hemato oncology.","authors":"Befikad Mandefro, Dereje Mengesha Berta, Amanuel Kelem, Bisrat Birke Teketelew, Abateneh Melkamu, Yalew Much, Zewdu Mulatie, Tiruneh Adane","doi":"10.1007/s12672-025-03169-9","DOIUrl":"10.1007/s12672-025-03169-9","url":null,"abstract":"Advanced diagnostic technologies are driving precision medicine to revolutionize the field of hemato-oncology, that enable personalized treatments based on detailed molecular and genetic profiles. Innovations like next-generation sequencing, digital PCR, and liquid biopsies have reshaped diagnosis, classification, and treatment decisions in hematologic cancers such as leukemia, lymphoma, and myeloma. Each technology offers unique strengths NGS provides broad mutational insights, digital PCR enables ultra-sensitive measurable residual disease detection, and flow cytometry delivers rapid, accessible analysis while also facing specific limitations. This review explores how these tools collectively improve early detection, prognostication, and tailored therapy, enhancing patient outcomes. However, challenges persist, including tumor clonal diversity, microenvironmental influences, and unequal access due to cost and regulatory barriers. Future progress hinges on integrating multi-omics data, enhancing diagnostic accuracy, and expanding accessibility to fully harness personalized hemato-oncology, paving the way for more effective, individualized treatments and improved survival.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1525"},"PeriodicalIF":2.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pseudogene pair-based prognostic model reveals LAT as a biomarker of immune response in head and neck squamous cell carcinoma. 基于假基因对的预后模型显示LAT是头颈部鳞状细胞癌免疫反应的生物标志物。

IF 2.9 4区医学

Discover. Oncology Pub Date : 2025-08-11 DOI: 10.1007/s12672-025-03316-2

Qin Ding, Wenquan Hong, Guanghao Chen, Ting Lin, Xiaochuan Chen, Hanxuan Yang, Wenqian Xu, Xinyi Hong, Jinghua Lai, Sufang Qiu, Jun Lu

{"title":"Pseudogene pair-based prognostic model reveals LAT as a biomarker of immune response in head and neck squamous cell carcinoma.","authors":"Qin Ding, Wenquan Hong, Guanghao Chen, Ting Lin, Xiaochuan Chen, Hanxuan Yang, Wenqian Xu, Xinyi Hong, Jinghua Lai, Sufang Qiu, Jun Lu","doi":"10.1007/s12672-025-03316-2","DOIUrl":"10.1007/s12672-025-03316-2","url":null,"abstract":"Background: Patients with head and neck squamous cell carcinoma (HNSCC) often exhibit only partial responses to immunotherapy, resulting in poor prognosis and potential overtreatment. While pseudogenes are known to significantly impact the tumor microenvironment (TME) and tumor prognosis, their specific role in HNSCC remains unclear.Methods: A prognostic risk profile for HNSCC patients was developed and validated using pseudogene pairs. The prognostic value of the risk signiture was assessed using survival analysis, ROC analysis, and Cox regression models. Correlations between our risk profile and immunologic characteristics of the TME were analyzed, with TIDE scores used to predict immunotherapy responses. LAT, identified as a central gene in the risk model through WGCNA and Friend analysis, was further investigated. LAT expression and its association with immune cells and immune checkpoints within the TME were examined using an internal cohort and immunofluorescence.Results: The model based on pseudogene pairs demonstrated strong prognostic power, with significantly longer overall survival in low-risk patients compared to high-risk ones. Additionally, risk scores were inversely related to immune infiltration and predictive of immunotherapy response. LAT, identified as a potential hub gene in the low-risk group, showed stable performance across multiple validation sets and was positively correlated with T cell infiltration and high expression in an inflammatory TME.Conclusion: A pseudogene pair-based survival prediction model for HNSCC was developed and validated, providing valuable insights for HNSCC treatment. LAT may serve as a novel biomarker for predicting immune response.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1528"},"PeriodicalIF":2.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0